Alvotech, Finesse Solutions Partner in BiomanufacturingBy
Alvotech, an independent sister company of the pharmaceutical company Alvogen, and Finesse Solutions Inc., a provider of turnkey single-use upstream bio-processing equipment, have formed a partnership under which Alvotech will provide manufacturing and laboratory technology through the Finesse’s SmartFactoryÂ® GMP manufacturing platform suite. SmartFactoryÂ® is single-use cGMP bio-manufacturing capacity by which Alvotech will use to expand its biosimilars business. Alovtech had announced in December 2013 that it plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech's current biosimilar assets include follow-on versions of leading monoclonal antibodies molecules, which will be brought to market by 2018, according to the company.